Squaric Acid 0.1%

Route: Topical application to scalp (for alopecia areata) or affected skin (for warts).

• Sensitization phase: A single 2% SADBE application (by clinician) to a small area (e.g., inner arm) to establish contact hypersensitivity over 2 weeks.
• Treatment phase: Starting at 0.001–0.01% (titrated upward), SADBE is applied to the affected scalp or skin area weekly or biweekly; 0.1% is a maintenance or escalated concentration.
• Applied with a cotton swab or gloved finger; patient or caregiver applies at home after initial sensitization.
• Leave on for 24–48 hours, then wash off. Mild erythema and pruritus are expected signs of adequate sensitization.
• Avoid contact with eyes, mouth, and mucous membranes.

Dosing is prescriber-directed and follows a sensitization-then-maintenance protocol:

• Sensitization: Single 2% SADBE application by clinician to establish DTH response; re-sensitization may be required if response wanes.
• Maintenance treatment: Weekly to biweekly topical application of 0.001%–0.1% SADBE to affected areas; concentration is titrated to produce mild erythema and pruritus (indicating adequate immune stimulation) without blistering or severe reactions.
• The 0.1% concentration is typically a mid-to-high maintenance dose; prescriber adjusts based on clinical response and tolerability.
• Response assessment at 3–6 months; treatment may continue for 12–24 months or longer.

• SADBE (contact immunotherapy): After primary sensitization, repeat low-dose application to the target site triggers a Type IV (T-cell-mediated) delayed hypersensitivity reaction. In alopecia areata, this is theorized to work via several mechanisms: (1) antigen competition—the DTH response recruits CD4+ T-helper cells and CD8+ regulatory T cells that outcompete or suppress autoreactive T cells attacking hair follicle autoantigens; (2) cytokine shift—local inflammation shifts the follicular immune environment from a Th1-dominant (IFN-γ, IL-2, TNF-α) to a more Th2-dominant profile, which is less follicle-destructive; (3) downregulation of MHC class I on follicle epithelium, restoring immune privilege. In warts, SADBE-induced inflammation may facilitate immune clearance of HPV-infected keratinocytes.

Indication context: SADBE contact immunotherapy is an established off-label treatment for moderate-to-severe alopecia areata (AA), particularly patchy and totalis/universalis variants that have not responded to first-line therapies (intralesional or topical corticosteroids, minoxidil). Response rates of 30–85% for partial or complete hair regrowth are reported in published case series, with highest responses in patchy AA of shorter duration. It is also used for recalcitrant common and plantar warts.

Monitoring:

• Assess for adequate sensitization response (mild erythema, pruritus) at each treatment visit.
• Photograph affected areas at baseline and at 3-month intervals to document hair regrowth or lesion regression.
• Monitor for excessive reactions: severe eczematous dermatitis, blistering, or regional lymphadenopathy—reduce concentration if these occur.
• Avoid systemic immunosuppression concurrently (may blunt DTH response).
• Advise patient to avoid sun exposure to treated areas during treatment (photosensitivity risk).

Contraindications:

• Known hypersensitivity to squaric acid derivatives.
• Active inflammatory or infected skin at the application site.
• Pregnancy and breastfeeding: safety not established; avoid use.
• Immunocompromised patients: use with caution; risk of exaggerated or uncontrolled inflammatory reaction.

Warnings & Precautions:

• Severe contact dermatitis with blistering, weeping, or ulceration may occur at excessive concentrations; reduce dose and frequency.
• Vitiligo (depigmentation) has been reported as a side effect of SADBE contact immunotherapy; advise patients of this risk.
• Regional lymphadenopathy (draining nodes) is common and expected; persistent or painful adenopathy warrants evaluation.
• Avoid sunlight or UV exposure to treated area during treatment (erythema worsened by UV).
• SADBE is a chemical sensitizer—healthcare providers and caregivers should wear gloves when handling; avoid inadvertent self-sensitization.

Drug Interactions:

• Systemic immunosuppressants (corticosteroids, methotrexate, JAK inhibitors): may inhibit the DTH response and reduce SADBE efficacy; discuss with prescriber before combining.

Common Side Effects: Erythema, pruritus, and mild eczematous reaction at application site (expected and necessary for efficacy); regional lymphadenopathy; urticaria (rare); vitiligo (rare); hyperpigmentation.

Store in amber glass or opaque container at room temperature (15–25°C) away from light and heat. SADBE is light- and heat-sensitive; degradation can occur if exposed to sunlight or high temperatures. Do not freeze. Keep tightly capped. Use within the beyond-use date assigned by Genesis Compounding per USP <795> guidelines. Keep out of reach of children and away from those not intended for treatment (risk of unintended sensitization).

What is squaric acid and how does it treat alopecia areata?

Squaric acid dibutylester (SADBE) is a contact sensitizer that produces a controlled immune reaction when applied to the skin. In alopecia areata, the immune system mistakenly attacks hair follicles. Repeated low-dose SADBE application creates a competing immune response that diverts or suppresses the follicle-attacking T cells, allowing hair to regrow in many patients.

Will I experience a reaction every time I apply it?

Yes—a mild reaction (redness, itch) is expected and necessary; it indicates the treatment is working. If there is no reaction, the concentration may need to be increased. If the reaction is severe (blistering, weeping), contact your prescriber to reduce the concentration.

How long does treatment take?

Many patients require 3–6 months before visible hair regrowth begins. Treatment often continues for 12–24 months or longer. Response varies widely depending on disease extent and duration.

Is this FDA-approved?

SADBE contact immunotherapy is not FDA-approved for any indication. It is used off-label based on published clinical evidence. This preparation is a patient-specific 503A compounded preparation from Genesis Compounding, dispensed only with a valid prescriber order.

Can this be used for warts?

Yes. Squaric acid contact immunotherapy is also used off-label for recalcitrant warts, where it stimulates an immune response that facilitates clearance of HPV-infected tissue. Your prescriber will determine if this is appropriate for your case.